Facts

Demant at a glance

We operate globally with a local presence through our companies in more than 30 countries and through trusted distributors in more than 130 countries. This way, we combine the best of two worlds: centralised and standardised processes that value local presence and initiatives.

Adding to our global orientation is a local presence. As a company represented in many countries, we act as a good citizen in the community. Besides from expected compliance with rules and regulations, this good citizenship includes the ambition that our employees and products contribute positively to the development of the community.

Market

Demant covers four business activities: traditional hearing instruments, hearing implants, diagnostic equipment and personal communication.

We are the only company in the world that covers these four areas, and we harvest significant synergies from this unique position. Synergies that will help millions of people experience the joy of hearing for many years to come. Just as the Demant family envisioned it when they founded and developed the company during the twentieth century.

With our approach to hearing healthcare and our complete product range, Demant, our customers and partners are fully equipped to help people with various kinds of hearing loss connect with the world and live their lives to the fullest.

Our unique position is a great advantage in a market that is growing. The hearing healthcare market represents a wholesale value of USD 6.5 billion per year, with Europe and North America being by far the largest markets.

Global tracking of hearing loss, e.g. MarkeTrak, EuroTrak and JapanTrak, shows that around 1 in 10 people over the age of 50 is living with a hearing loss. Approximately 15 million hearing aids and 85,000 hearing implants are sold every year, and the annual market growth is 4-6% in units, largely driven by the underlying demographic development, which is growing approx. 5% in value annually.

Ownership structure

William Demant Foundation is the majority owner of Demant A/S (55-60%) through William Demant Invest A/S, which is the 100% owned holding company for William Demant Foundation’s investment activities.

In addition to Demant A/S, William Demant Invest A/S holds the majority ownerships of the orthopedics company Össur hf. (52% ownership) and Vision RT Ltd., which develops camera systems for surface-guided radiation therapy (89% ownership). Moreover, William Demant Invest A/S is the largest shareholder in Vitrolife AB, CellaVision AB and Revenio Oyj, which are engaged in developing medical equipment for fertility treatment, blood cell analysis and diagnosis of eye diseases, respectively. William Demant Invest A/S holds between 10% and 30% of the shares in these companies. Finally, William Demant Invest A/S is the largest shareholder in the listed real estate and service company Jeudan A/S (42% ownership) and owns together with KIRKBI A/S 50% of the German offshore wind farm, Borkum Riffgrund 1. Össur hf. and Jeudan A/S are listed in Denmark, while Vitrolife AB and CellaVision AB are listed in Sweden and Revenio Oyj is listed in Finland.